Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY1272 in Late Phase Solid Tumors or EGFRm+ NSCLC
NCT06218940Phase 1Not yet recruiting
- Sponsor
- Newsoara Biopharma
- Start
- Dec 2024
- Primary completion
- Dec 2026
01
Overview
Phase 1, open-label trial of HY1272 in solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Newsoara Biopharma. Primary endpoints: Safety and Tolerability of HY1272 and Pharmacokinetics of HY1272. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
HY1272
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06218940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218940.